Vedanta Biosciences said it significantly reduced headcount and refocused operations to concentrate resources on its lead live bacterial consortium, VE303, which is in Phase 3 development for prevention of recurrent Clostridioides difficile infection. The company cited prior phase 2 data and strategic need to prioritize the VE303 program while seeking additional capital. Vedanta’s move follows prior portfolio reprioritization after a Phase 2 failure in a separate program; the company noted VE303’s Phase 3 is targeted for completion in 2027. For investors and microbiome developers: workforce reductions to preserve runway for a single late‑stage program underscore financing pressure in microbiome therapeutics despite promising early clinical signals in the field.